Natera has completed its acquisition of Foresight Diagnostics in a transaction that expands its position in the fast-growing market for molecular residual disease testing and enhances its technological advantage across solid tumors and hematologic cancers. The deal includes an upfront all-stock consideration valued at $275 million, with an additional $175 million tied to revenue and reimbursement milestones.
Foresight brings to Natera an ultrasensitive phased variant technology with reported performance reaching a limit of detection below 0.1 parts per million. Its PhasED-Seq platform targets phased variants and has been validated across more than 40 publications and collaborations with over 30 biopharma and academic partners. The company was founded by Stanford University physicians and scientists Maximilian Diehn, Ash Alizadeh, David Kurtz, and Jake Chabon, who serve as the chief scientific officer and chief executive officer, respectively.
The acquisition expands Natera’s intellectual property portfolio, which includes more than five hundred issued or pending patents. It accelerates the company’s work in lymphoma, an area where Foresight has built significant clinical momentum. Earlier in the year, Foresight data contributed to the inclusion of circulating tumor DNA MRD into the National Comprehensive Cancer Network Clinical Practice Guidelines for diffuse large B-cell lymphoma. Foresight’s CLARITY assay continues to support multiple prospective MRD-driven clinical trials.
Natera plans to integrate phased variants into its Signatera platform, offering enhanced performance across solid tumors. The research-use version is already available for biopharma and academic partners, with clinical launch expected in 2026. The combined companies will present 15 abstracts at the American Society of Hematology Annual Meeting, beginning December 6, including 7 oral presentations.
Support: Gibson, Dunn & Crutcher advised Natera, while Wilson Sonsini Goodrich & Rosati and Centerview Partners advised Foresight on the transaction.
KEY QUOTES:
“This acquisition reinforces Natera’s position at the forefront of precision oncology. Foresight’s phased variant technology and leadership in lymphoma complement Natera’s strong capabilities in personalized MRD testing, improving the value we can deliver to patients, clinicians, biopharma partners and the broader healthcare system.”
Steve Chapman, Chief Executive Officer, Natera
“Foresight’s mission has always been to improve the lives of cancer patients worldwide through innovative diagnostics. As we join Natera, I’m deeply grateful to our employees, partners and investors who have helped bring us to this moment. Together, we can realize this mission on a far greater scale, accelerating the pace of discovery across both hematologic and solid tumors.”
Jake Chabon, Ph.D., Chief Scientific Officer and Chief Executive Officer, Foresight Diagnostics
